Abstract
The therapeutic efficacy of oral N-acetylcysteine (NAC) and ambroxol as compared with the effect of placebos was studied in 36 cystic fibrosis (CF) patients with mild to moderate pulmonary disease. The patients were randomly assigned to one of three regimens, matched on the basis of age and Chrispin-Norman scores. The trial was conducted over a period of 12 weeks. Patients were assessed clinically and by extensive pulmonary function techniques (body-plethysmography, maximal expiratory flow-volume curves, trapped air determination). Although no clinical differences could be observed between the three groups, significant impairment in the placebo group was found for trapped air and FEV1 when compared to the active groups, suggesting a therapeutic effect of ambroxol and NAC in CF.
This is a preview of subscription content, access via your institution.
Abbreviations
- CF:
-
cystic fibrosis
- NAC:
-
N-acetylcysteine
- Rsaw :
-
airways resistance
- FRC:
-
functional residual capacity
- TGV:
-
thoracic gas volume
- ERV:
-
expiratory reserve volume
- IVC:
-
inspiratory vital capacity
- sRaw :
-
specific airways resistance
- sGaw :
-
specific conductance
- RV:
-
residual volume
- MEFV:
-
maximal expiratory flow volume
- FEV1 :
-
forced expiratory volume in 1 s
- FVC:
-
forced vital capacity
- PEFR:
-
peak expiratory flow rate
References
Boman G, Bäcker U, Larsson S, Melander B, Wahlander L (1983) Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 64:405–415
Chrispin AR, Norman AP (1974) The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol 2:101–106
Denton R, Kwart H, Litt M (1967) N-acetylcysteine in cystic fibrosis. Am Rev Respir Dis 95:643–651
Du Bois AB, Botelho SY, Bedell GN, Marshall R, Comroe JH (1956) A rapid plethysmographic method for measuring thoracic gas volume: A comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. J Clin Invest 35 I:322–326
Engström I, Escardó FE, Karlberg P, Kraepelien S (1958) Respiratory studies in children. VI. Timed vital capacity in healthy children and in symptom free asthmatic children. Acta Paediatr 48:114–120
Genghini M, Camerota G, Zavattini G, Curti PC (1981) The activity of NA 872 (Mucosolvan) in chronic broncho-pulmonary disorders. Gazz Med Ital 140:189–195
Geubelle F (1965) Contribution à l'étude fonctionelle du poumon de l'enfant sain et de l'enfant asthmatique. Duculot (ed), Gembloux
Geubelle F (1973) Volume pulmonaire, capacités ventilatoire chez l'enfant. Univ Presse, Liège
Götz M, Kraemer R, Kerrebijn KF, Popow C (1980) Oral acetylcysteine in cystic fibrosis. A co-operative study. Eur J Respir Dis 61 [Suppl] 111:122–126
Hirsch SR, Zastrow JE, Kory RC (1969) Sputum liquifying agents: A comparative in vitro evaluation. J Lab Clin Med 74:346–353
Hofmann D, Geubelle F, Le Clerc-Foucart J (1975) Activité du Th. 1165 sur la fonction de l'enfant atteint d'un syndrome asthmatique dans l'intervalle entre les crises ou les épisodes de dyspnée. Rev Med Liège 30 II:46–53
Lamarre A, Reilly BJ, Bryan AC, Levison H (1972) Early detection of pulmonary function abnormalities in cystic fibrosis. Pediatrics 50 II:291–297
Landau LI, Phelan PD (1973) The spectrum of cystic fibrosis. Am Rev Respir Dis 108:593–602
Logvinoff MM, Mossay C, Geubelle F (1976) Oxygen tension in arterialized cutaneous blood and lung function in asthmatic children. Acta Paediatr Belg 29:239–244
Mitchell EA, Elliott RB (1982) Controlled trial of oral N-acetylcysteine in cystic fibrosis. Austr Paediatr J 18:40–42
Morrow PE (1974) Aerosol characterization and deposition. Am Rev Respir Dis 110 [Suppl]:88–99
Püschmann S, Engelhorn R (1978) Pharmakologische Untersuchungen des Bromhexin-Metaboliten Ambroxol. Arzneimittelforsch 28 I:889–898
Reas HW (1964) The use of N-acetylcysteine in the treatment of cystic fibrosis. J Pediatr 65:542–557
Rodenstein D, De Coster A, Gazzaniga A (1978) Pharmacokinetics of oral acetylcysteine: Absorption, binding and metabolism in patients with respiratory disorders. Clin Pharmacokinet 3: 247–254
Rodenstein DO, Stanescu DC (1982) Reassessment of lung volume measurement by helium dilution and by body plethysmography in chronic air-flow obstruction. Am Rev Respir Dis 126:1040–1044
Schnellbächer F (1981) Lung function testing by means of the simple and advanced forced oscillation method. Dr. Curt Haefner Verlag, Heidelberg
Sheffner AL, Medler EM, Jacobs LW, Sarett HP (1964) The in vitro reduction of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis 90:721–729
Shwachman H, Kulczycki LL (1958) Long-term study of 105 patients with cystic fibrosis. Am J Dis Child 96:6–15
Stephan U, Böwing B, Goering U, Wiesemann HG, Reinhardt M, Hirche H, Brandt H (1980) Acetylcysteine in the oral mucolytic treatment of cystic fibrosis. Eur J Respir Dis 61 [Suppl] 111:127–131
Wönne R, Plaut G, Posselt HG, Stöver B, Hofmann D, Bender SW (1984) The influence of mechanical chest wall percussion on lung function in patients with mild cystic fibrosis. Prax Klin Pneumol 38:98–101
Zapletal A (1981) Small airway function in children and adolescents in health and disease. Prog Resp Res 17:52–67
Zapletal A, Stefanová J, Horák J, Vávrová V, Samánek M (1983) Chest physiotherapy and airway obstruction in patients with cystic fibrosis—a negative report. Eur J Respir Dis 64:426–433
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratjen, F., Wönne, R., Posselt, HG. et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 144, 374–378 (1985). https://doi.org/10.1007/BF00441781
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00441781